tetragastrin and Psychotic-Disorders

tetragastrin has been researched along with Psychotic-Disorders* in 1 studies

Other Studies

1 other study(ies) available for tetragastrin and Psychotic-Disorders

ArticleYear
Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1999, Volume: 20, Issue:2

    Systemic injections of cholecystokinin (CCK), a "gut-brain" peptide, have been shown to modulate brain dopamine function and produce neuroleptic-like effects on such dopamine-regulated behaviors as locomotor activity. However, clinical trials of CCK agonists in schizophrenia patients showed mixed results. To re-examine the antipsychotic potential of CCK-based treatments, we examined systemic injections of CCK analogs in an animal model with strong face and construct validity for sensorimotor-gating deficits seen in schizophrenia patients and with strong predictive validity for antipsychotic drug activity. Prepulse inhibition (PPI) occurs when a weak acoustic lead stimulus ("prepulse") inhibits the startle response to a sudden loud sound ("pulse"). PPI is significantly reduced in schizophrenia patients and rats treated with dopamine agonists. Antipsychotics reverse decreased PPI in rats to a degree highly correlated with their clinical efficacy. Subcutaneous (s.c.) injections of caerulein (10 micrograms/kg) a mixed CCKA/B agonist, partially reversed amphetamine-induced reduction of PPI; whereas, s.c. haloperidol (0.5 mg/kg) totally reversed amphetamine-induced disruption of PPI. Caerulein's effect on PPI was blocked by pretreatment with a CCKA antagonist (devazepide) but not a CCKB antagonist (L-365,260). CCK-4, a preferential CCKB agonist, had no significant effect on PPI. These results suggest that caerulein produces a weak neuroleptic-like effect on PPI that is mediated by stimulation of CCKA receptors. Possible circuities in this effect are discussed. In a separate experiment, s.c. caerulein produced to a more potent neuroleptic-like profile on amphetamine-induced hyperlocomotion, suggesting that selection of preclinical paradigms may be important in evaluating the antipsychotic potential of CCK-based treatments.

    Topics: Animals; Antipsychotic Agents; Behavior, Animal; Ceruletide; Cholecystokinin; Gastrointestinal Agents; Haloperidol; Injections, Subcutaneous; Male; Motor Activity; Psychotic Disorders; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Reflex, Startle; Tetragastrin

1999